HC Wainwright Has Positive Forecast for MIST FY2026 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Milestone Pharmaceuticals in a research note issued to investors on Monday, December 15th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.70) for the year, up from their prior forecast of ($0.71). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2027 earnings at ($0.61) EPS, FY2028 earnings at $0.53 EPS and FY2029 earnings at $1.03 EPS.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday. Wells Fargo & Company boosted their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Monday. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Milestone Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Milestone Pharmaceuticals Stock Down 3.3%

NASDAQ:MIST opened at $2.08 on Wednesday. The business’s fifty day moving average price is $2.19 and its 200 day moving average price is $1.93. The firm has a market capitalization of $177.15 million, a price-to-earnings ratio of -2.54 and a beta of 0.41. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Sapient Capital LLC acquired a new position in shares of Milestone Pharmaceuticals during the third quarter worth approximately $25,000. Bay Rivers Group bought a new position in Milestone Pharmaceuticals during the second quarter worth $28,000. Bank of America Corp DE raised its stake in Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after purchasing an additional 16,044 shares during the last quarter. Stephenson & Company Inc. acquired a new position in Milestone Pharmaceuticals during the 3rd quarter valued at $40,000. Finally, Creative Planning boosted its holdings in Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.